Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

Cross-reactive neutralizing antibodies (NAbs) are found in the sera of many HIV-1-infected individuals, but the virologic basis of their neutralization remains poorly understood. We used knowledge of HIV-1 envelope structure to develop antigenically resurfaced glycoproteins specific for the structur...

Full description

Saved in:
Bibliographic Details
Published inScience (American Association for the Advancement of Science) Vol. 329; no. 5993; pp. 856 - 861
Main Authors Wu, Xueling, Yang, Zhi-Yong, Li, Yuxing, Hogerkorp, Carl-Magnus, Schief, William R, Seaman, Michael S, Zhou, Tongqing, Schmidt, Stephen D, Wu, Lan, Xu, Ling, Longo, Nancy S, McKee, Krisha, O'Dell, Sijy, Louder, Mark K, Wycuff, Diane L, Feng, Yu, Nason, Martha, Doria-Rose, Nicole, Connors, Mark, Kwong, Peter D, Roederer, Mario, Wyatt, Richard T, Nabel, Gary J, Mascola, John R
Format Journal Article
LanguageEnglish
Published United States American Association for the Advancement of Science 13.08.2010
The American Association for the Advancement of Science
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cross-reactive neutralizing antibodies (NAbs) are found in the sera of many HIV-1-infected individuals, but the virologic basis of their neutralization remains poorly understood. We used knowledge of HIV-1 envelope structure to develop antigenically resurfaced glycoproteins specific for the structurally conserved site of initial CD4 receptor binding. These probes were used to identify sera with NAbs to the CD4-binding site (CD4bs) and to isolate individual B cells from such an HIV-1-infected donor. By expressing immunoglobulin genes from individual cells, we identified three monoclonal antibodies, including a pair of somatic variants that neutralized over 90% of circulating HIV-1 isolates. Exceptionally broad HIV-1 neutralization can be achieved with individual antibodies targeted to the functionally conserved CD4bs of glycoprotein 120, an important insight for future HIV-1 vaccine design.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
Present address: Department of Molecular Genetics, Novo Nordisk A/S, Novo Nordisk Park, 2760 Måløv, Denmark.
These authors contributed equally to this work.
Present address: Department of Immunology and Microbial Science, and IAVI Center for Neutralizing Antibody at TSRI, Scripps Research Institute, La Jolla, CA 92037, USA.
ISSN:0036-8075
1095-9203
1095-9203
DOI:10.1126/science.1187659